AAS, growth hormone, and insulin abuse: Psychological and neuroendocrine effects

Therapeutics and Clinical Risk Management

Volumn 4, Issue 3, 2008, Pages 587-597

  Graham, Michael R ^a   Evans, Peter ^b   Davies, Bruce ^a   Baker, Julien S ^a  

^a UNIVERSITY OF GLAMORGAN   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

AAS; Cosmesis; Growth hormone; Insulin; Performance; Strength

Indexed keywords

ACIPIMOX; ANABOLIC ANDROGENIC STEROID; ESTRADIOL; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; INSULIN; LEUCINE; LEUCINE[13 CYSTEINE]; MEDROXYPROGESTERONE ACETATE; MYOSTATIN; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATREM; STEROID; TESTOSTERONE;

ANTHROPOMETRY; ANXIETY; ATHLETE; BIOCHEMISTRY; COMORBIDITY; CONVULSION; CREUTZFELDT JAKOB DISEASE; DEPRESSION; DOPING; DRUG DOSE COMPARISON; EUPHORIA; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HORMONE ACTION; HUMAN; HYPERTROPHY; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LEAN BODY WEIGHT; MENTAL DISEASE; MUSCLE STRENGTH; NEUROENDOCRINE DISEASE; OBESITY; PHYSICAL PERFORMANCE; PROTEIN EXPRESSION; PSYCHOLOGICAL WELL BEING; REVIEW; RISK FACTOR; SELF POISONING; SUBSTANCE ABUSE; UNSPECIFIED SIDE EFFECT;

EID: 47849122935     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Argetsinger LS, Campbell GS, Yang X, et al. 1993. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell, 74:237-44.
2. Astrom C, Pedersen SA, Lindholm J. 1990. The influence of growth hormone on sleep in adults with growth hormone deficiency. Clinical Endocrinol (Oxf), 43:143-9.
3. Baker JS, Graham MR, Davies B. 2006. "Steroid" and prescription medicine abuse in the health and fitness community; a regional study. Eur J Intern Med, 17:479-84.
4. Baumann G. 1991. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev, 12:424-49.
5. Berggren A, Ehrnborg C, Rosen T, et al. 2005. Short-term administration of supraphysiological recombinant human growth hormone (GB) does not increase maximum endurance exercise capacity in healthy, active young men and females with normal GB-insulin-like growth factor I axes. J Clin Endocrinol Metab, 90:3268-73.
6. Bhasin S, Storer TW, Berman N, et al, 1996. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med, 335:1-7.
7. Biolo G, Fleming RYD, Wolfe RD. 1995. Physiologic hyperinsulinaemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. J Clin Invest, 95:811-19.
8. Blackman MR, Sorkin JD, Münzer T, et al. 2002. Growth hormone and sex steroid administration in healthy aged women and men. J Am Med Assoc, 288:2282-92.
9. Bonadonna RC, Saccomani MP, Cobelli C, et al. 1993. Effect of Insulin on System A Amino Acid Transport in Human Skeletal Muscle. J Clin Invest, 91:514-21.
10. Boroujerdi MA, Umpleby AM, Jones RH, et al. 1995. A simulation model for glucose kinetics and estimates of glucose utilization rate in type I diabetic patients. Am J Physiol, 268:766-74.
11. Brill KT, Weltman AL, Gentili A, et al. 2002. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab, 87:5649-57.
12. Brown RJ, Adams JJ, Pelekanos RA, et al. 2005. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol, 12:814-21.
13. Cassidy EM, O'Halloran DJ, Barry S. 1999. Insulin as a substance of misuse in a patient with insulin dependent diabetes mellitus. BMJ, 319:1417-18.
14. Coghlan A. 2001. Athletes may be increasingly abusing insulin [online]. New Scientist, August 8. Accessed on December 12, 2007. URL: http://www.newscientist.com/article/ dn1129-athletes-may-be-increasingly-abusing-insulin.html.
15. Crist DM, Peake GT, Egan PA, et al. 1988. Body composition response to exogenous GH during training in highly conditioned adults. J Appl Physiol, 65:579-84.
16. Dahl RE, Birmaher B, Williamson DE, et al. 2000. Low growth hormone response to growth hormone-releasing hormone in child depression. Biol Psychiatry, 48:981-8.
17. Dawson RT. 2001. Drugs in sport. The role of the physician. J Endocrinol, 170:55-61.
18. Deyssig R, Frisch H, Blum WF, et al. 1993. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol (Copenh), 128:313-18.
19. Doessing M, Kjaer M. 2005. Growth hormone and connective tissue in exercise. Scand J Med Sci Sports, 15:202-10.
20. Duchaine D. 1983. Underground steroid handbook, 1st ed. California: HLR Technical Books, p 84.
21. Ehrnborg C, Ellegard L, Bosaeus I, et al. 2005. Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults. Clin Endocrinol (Oxf), 62:449-57.
22. Elkin SL, Brady S, Williams IP. 1997. Bodybuilders find it easy to obtain insulin to help them in training. BMJ, 314:1280.
23. Eriksson A, Kadi F, Malm C, et al. 2005. Skeletal muscle morphology in power-lifters with and without anabolic steroids. Histochem. Cell Biol, 124:167-75.
24. Evans PJ, Lynch RM. 2003. Insulin as a drug of abuse in body building. Br J Sports Med, 37:356-7.
25. Fryburg DA, Gelfand RA, Barrett EJ. 1991. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am J Physiol, 260:499-504.
26. GonderFreerick LA, Clarke WL, Cox DJ. 1997. The emotional, social and behavioural implications of insulininduced hypoglycemia. Semin Clin Neuropsychiatry, 2:57-65.
27. GonderFreerick LA, Cox DJ, Bobbitt SA. 1989. Mood changes associated with fluctuations in insulindependent diabetes mellitus. Health Psychol, 8:45-9.
28. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, et al. 1998. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA, 95:14938-43.
29. Gotherstrom G, Bengtsson BA, Sunnerhagen KS, et al. 2005. The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clin Endocrinol (Oxf), 62:105-13.
30. Gottesman I, Mandarino L, Verdonk C, et al. 1982. Insulin increases the maximum velocity of glucose uptake without altering the Michaelis constant in man. J Clin Invest, 70:1310-14.
31. Grace FM, Baker JS, Davies B. 2001. Anabolic androgenic steroid (AAS) use in recreational gym users - A regional sample of the Mid-Glamorgan area. J Substance Use, 12:145-53.
32. Graham MR, Baker JS, Evans P, et al. 2007a. Recombinant human growth hormone in abstinent androgenic-anabolic steroid use: Psychological, endocrine, and trophic factor effects. Curr Neurovasc Res, 4:9-18.
33. Graham MR, Davies B, Hullin D, et al. 2007b. Short-term recombinant human growth hormone administration improves respiratory function in abstinent anabolic-androgenic steroid users. Growth Horm IGF Res, 17:201-9.
34. Gruber AJ, Pope HG Jr. 1999. Compulsive weight lifting and anabolic drug abuse among women rape victims. Compr Psychiatry, 40:273-7.
35. Gruber AJ, Pope HG Jr. 2000. Psychiatric and medical effects of anabolic-androgenic steroid use in women Psycother Psychosom, 69:19-26.
36. Gullestad L, Birkeland K, Bjonerheim R. 1998. Exercise capacity and hormonal response in adults with childhood Onset growth hormone deficiency during long-term somatropin treatment. Growth Horm IGF Res, 8:377-84.
37. Hamer D, Sanjeev D, Butterworth E, et al. 1991. Using the Hospital Anxiety and Depression Scale to screen for psychiatric disorders in people presenting with deliberate self-harm. Br J Psychiatry, 158:782-4.
38. Harro J, Rimm H, Harro M, et al. 1999. Association of depressiveness with blunted growth hormone response to maximal physical exercise in young healthy men. Psychoneuroendocrinology, 24:505-17.
39. Hart SP, Frier BM. 1998. Causes, management and morbidity of acute hypoglycaemia in adults requiring a hospital admission. Quart J Med, 91:505-10.
40. Hartgens F, Kuipers, H. 2004. Effects of androgenic-anabolic steroids in athletes. Sports Med, 34:513-14.
41. Hartgens F, Rietjens G, Keizer HA, et al. 2004. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med, 38:253-9.
42. Haupt HA, Rovere GD. 1984. Anabolic steroids: a review of the literature. Am J Sports Med, 12:469-84.
43. Healy ML, Gibney J, Russell-Jones DL, et al. 2003. High dose growth hormone exerts an anabolic effect at rest and during exercise in endurance-trained athletes. J Clin Endocrinol Metab, 11:5221-6.
44. Healy ML, Gibney J, Pentecost C, et al. 2006. Effects of high-dose growth hormone on glucose and glycerol metabolism at rest and during exercise in endurance-trained athletes. J Clin Endocrinol Metab, 9:320-7.
45. Herrmann C. 1997. International experiences with the Hospital Anxiety and Depression Scale, a review of validation data and clinical results. J Psychosom Res, 42:17-41.
46. Horber FF, Haymond MW. 1990. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest, 86:265-72.
47. Iranmanesh A, Lizarralde G, Velduis JD. 1991. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab, 73:1081-8.
48. Irving BA, Patrie JT, Anderson SM, et al. 2004. The effects of time following acute growth hormone administration on metabolic and power output measures during acute exercise. J Clin Endocrinol Metab, 89:4298-305.
49. Janson C, Bjornsson E, Hetta J, et al. 1994. Anxiety and depression in relation to respiratory symptoms and asthma. Am J Respir Crit Care Med, 149:930-4.
50. Jenkins PJ. 2001. Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res, 11:71-7.
51. Johannsson G, Grimby G, Sunnerhagen KS, et al. 1997. Two years of growth hormone (GH) treatment increases isometric and isokinetic muscle strength in GH-deficient adults. JClin Endocrinol Metab, 82:2877-84.
52. Kaminer Y, Robbins DR. 1989. Insulin misuse: a review of an over-looked psychiatric problem. Psychosomatics, 30:19-24.
53. Karakula H, Grzywa A, Spila B, et al 1996. Use of Hospital Anxiety and Depression Scale in psychosomatic disorders. Psychiatr Pol, 30:653-67.
54. Kimball SR, Vary TC, Jefferson LS. 1994. Regulation of protein synthesis by insulin. Ann Rev Physiol, 56:321-48.
55. Konrad C, Schupfer G, Wietlisbach M, et al. 1998. Insulin as an anabolic: hypoglycaemia in the bodybuilding world. Anaesthesiol Intensivmed Schmerzther, 33:461-3.
56. Kovacs M, Goldston D, Obrosky DS, et al. 1997. Psychiatric disorders in youths with IDDM: rates and risk factors. Diabetes Care, 20:36-44.
57. Lange KH, Larsson B, Flyvberg A, et al. 2002a. Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. J Clin Endocrinol Metab, 87:4966-75.
58. Lange KH, Andersen JL, Beyer N, et al. 2002b. GH admin changes myosin heavy chain isoforms in skeletal muscle but does not augment muscle strength or hypertrophy, either alone or combined with resistance exercise training in healthy elderly men. J Clin Endocrinol Metab, 87:513-23.
59. Le Roith D, Scavo L, Butler A. 2001. What is the role of circulating IGF-I? Trends Endocrinol Metab, 12:48-52.
60. Lim VS, Yarasheski KB, Crowley JR, et al. 2003. Insulin is protein-anabolic in chronic renal failure patients. J Am Soc Nephrol, 14:2297-304.
61. Liu W, Thomas SG, Asa SL, et al. 2003. Myostatin is a skeletal muscle target of growth hormone anabolic action. J Clin Endocrinol Metab, 88:5490-b.
62. Lustman PJ, Griffith LS, Clouse RE, et al. 1997. Effects of nortriptyline on depression and glycemic control in diabetes. Psychosom Med, 59:241-50.
63. Mahajan T, Crown A, Checkley S, et al. 2004. Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. Eur J Endocrinol, 151:325-32.
64. Martin CR, Lewin RJ, Thompson DR. 2003. A confirmatory factor analysis of the Hospital Anxiety and Depression Scale in coronary care patients following acute myocardial infarction. Psychiatry Res, 120:85-94.
65. Mauras N, Haymond MW. 2005. Are the metabolic effects of GH and IGB-I separable. Growth Horm IGF Res, 15:19-27.
66. McGauley GA. 1989. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand, 356:70-2.
67. McMillan CV, Bradley C, Giannoulis M, et al. 2003. Preliminary development of a new individualised questionnaire measuring quality of life in older men with age-related hormonal decline: the A-RHDQoL. Health Qual Life Outcomes, 1:51.
68. Melmed S. 2006. Medical progress: Acromegaly. N Engl J Med, 14:2558-73.
69. Milani D, Carmichael JD, Welkowitz J, et al. 2004. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab, 89:2271-4.
70. Morris AD, Boyle DI, McMahon AD, et al. 1997. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulindependent diabetes mellitus. Lancet, 350:1505-10.
71. Nørrelund H, Nair KS, Nielsen S, et al. 2003. The decisive role of free fatty acids for protein conservation during fasting in humans with and without growth hormone. J Clin Endocrinol Metab, 88:4371-8.
72. Odie ELA. 1968. Insulin habituation and psychopathy. BMJ, 2:346.
73. O'Reilly KE, Rojo F, She QB, et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res, 66:1500-8.
74. Pagonis TA, Angelopoulos NV, Koukoulis GN, et al. 2006a. Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins. Eur Psychiatry, 21:563-9.
75. Pagonis TA, Angelopoulos NV, Koukoulis GN, et al. 2006b. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlates to the severity of abuse. Eur Psychiatry, 21:551-62.
76. Papadakis MA, Grady D, Black D, et al. 1996. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med, 124:708-16.
77. Papazisis G, Kouvelas D, Mastrogianni A, et al. 2007. Anabolic androgenic steroid abuse and mood disorder: a case report. Int J Neuropsychopharmacol, 10:291-3.
78. Pope HG Jr, Katz DL, Hudson JI. 1993. Anorexia nervosa and "reverse anorexia" among 108 male bodybuilders. Compr Psychiatry, 34:406-9.
79. Potter J, Clarke P, Gale EA, et al. 1982. Insulininduced hypoglycaemia in an accident and emergency department: the tip of an iceberg? BMJ, 285:1182-90.
80. Powrie JK, Bassett EE, Rosen T, et al. 2007. Detection of growth hormone abuse in sport. Growth Horm IGF Res, 17:220-6.
81. Rennie MJ. 2003. Claims for the anabolic effect of growth hormone. A case for the Emperor's new clothes. Br J Sports Med, 37:100-5.
82. Retsas S. 1972. Insulin abuse by a drug addict. BMJ, 4:792-3.
83. Rich JD, Dickinson BP, Merriman NA, et al. 1998. Insulin use by bodybuilders. JAMA, 279:1613.
84. Riva G, Molinari B. 1995. Body image and social attitude in growth-hormone-deficient adults. Percept Mot Skills, 80:1083-8.
85. Ruckzika L, Wettstein A, Kaegi H. 1935. Sexual hormone VIII Darstellung von Testosterone unter Anwendung gemischter Ester. Helv Chim Acta, 18:1478.
86. Rudman D, Feller AG, Nagraj HS, et al. 1990. Effect of human growth hormone in men over 60 years old. N Engl J Med, 323:1-6.
87. Rudman D, Feller AG, Cohn L, et al. 1991. Effect of human growth hormone on body composition in elderly men. Horm Res, 36:73-81.
88. Sato Y, Hayamizu S, Yamamoto C, et al. 1986. Improved insulin sensitivity in carbohydrate and lipid metabolism after physical training. Int J Sports Med, 7:307-10.
89. Savine R, Sönksen P. 2000. Growth hormone - hormone replacement for the somatopause? Horm Res, 53:37-41.
90. Scaramuzza A, Castellani G, Lorini R. 1996. Insulin abuse in an adolescent with insulindependent diabetes mellitus. Eur J Pediatr, 155:526.
91. Scarlett JA, Mako ME, Rubenstein AH, et al. 1977. Factitious hypoglycemia. Diagnosis by measurement of serum Cpeptide immunoreactivity and insulinbinding antibodies, N Engl J Med, 297:1029-32.
92. Schafer E. 1916. The endocrine organs. London: Longman, Green and Co.
93. Schuelke M, Wagner KR, Stolz LE, et al. 2004. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med, 350:2682-8.
94. Shahidi NT. 2001. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther, 23:1355-90.
95. Sinha A, Formica C, Tsalamandris C, et al. 1996. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabet Med, 13:40-6.
96. Sonksen PH. 2001. Insulin, growth hormone and sport. J Endocrinol, 170:13-25.
97. Sonksen PH, Sonksen J. 2000. Insulin: Understanding its action in health and disease. Br J Anaesthesia, 85:69-79.
98. Stabler B, Turner JR, Girdler SS, et al. 1992. Reactivity to stress and psychological adjustment in adults with pituitary insufficiency. Clin Endocrinol, 6:467-73.
99. Stouthart PJ, Deijen JB, Roffel M, et al. 2003. Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy. Psychoneuroendocrinology, 28:612-26.
100. Taaffe DR, Pruitt L, Reim J, et al. 1994. Effects of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab, 79:1361-6.
101. Takala J, Ruokonen E, Webster NR, et al. 1999. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med, 341:785-92.
102. Thomas SHL, Wisher MH, Brandenburg D, et al. 1979. Insulin action on adipocytes. Evidence that the anti-lipolytic and lipogenic effects of insulin are medicated by the same receptor. Biochem J, 184:355-60.
103. Wallace JD, Cuneo RC, Baxter R, et al. 1999. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab, 84:3591-601.
104. Weiss RD, Greenfield SF, Najavits LM, et al. 1998. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry, 59:172-4.
105. Wu Z, Bidlingmaier M, Dall R, et al. 1999. Detection of doping with human growth hormone. Lancet, 353:895.
106. Yarasheki KE, Campbell JA, Smith K. 1992. Effect of growth hormone and resistance exercise on muscle growth and strength in young men. Am J Physiol, 262:261-7.
107. Yarasheki KE, Zachwieja JJ, Angelopoulos TJ. 1993. Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J Appl Physiol, 74:3073-6.
108. Yarasheki KE, Zachwieja JJ, Campbell JA, et al. 1995. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol, 268:268-76.
109. Zachwieja JJ, Yarasheki KE. 1999. Does growth hormone therapy in conjunction with resistance exercise increase muscle force production and muscle mass in men and women aged 60 years or older? Phys Ther, 79:76-82.
110. Zigmond AS, Snaith RP. 1983. The hospital anxiety and depression scale. Acta Psychiatr Scand, 67:361-70.